K Yan, L Forman. Liver Transplantation; 2021; 27: 1623-1632. Open Access: Cannabinoid Use Among Liver Transplant Recipients
- 23.8% of liver transplant recipients reported current MJ use (of 538 who responded to survey
- Top reasons for MJ use were recreation (56.5%), anxiety (54.8%), and pain (53.2%)
- Among respondents, 21.0% currently used CBD, usually in the form of creams or lotions (58.9%) and to relieve pain (84.9%) and anxiety (31.1%)
The authors note that MJ (marijuana) use previously was not associated with adverse liver tranplant outcomes (in one study); however, there are “there are case reports of drug interactions resulting in tacrolimus toxicity in patients using MJ and CBD.” And, MJ by inhalation may increase the risk for pulmonary fungal/aspergillosis. The use of MJ was similar to previous data in the general Colorado population, “18.1% of adults aged 18 and older in Colorado had used MJ in the past month in 2017-2018, compared with 10.2% of adults nationally.”
My take: Cannaboid use is common in liver transplant recipients and in the general population. More data is needed to understand its safety.
Related blog posts:
- Legalized Cannabis Associated with Increased Vomiting and Dependency But What About Alcohol?
- Cannabis: feel better, worse Crohn’s disease
- Crohn’s Research: Going to Pot | gutsandgrowth
- Would Medical Marijuana Meet the Threshold for FDA Approval? | gutsandgrowth
- Medical Marijuana -Update | gutsandgrowth
- Should Medical Marijuana Get a Free Pass? | gutsandgrowth